Interleukin 1A blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment

Journal of Clinical Rheumatology

Volumn 18, Issue 6, 2012, Pages 310-311

  Diamantopoulos, Andreas P ^a,b   Brodin, Christer ^a   Hetland, Helene ^a   Haugeberg, Glenn ^a,b  

^a Hospital of Southern Norway Kristiansand   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

CPP crystal arthritis; Crystal arthritides; IL 1A blockade; Inflammation; Ultrasound

Indexed keywords

CALCIUM PYROPHOSPHATE; DOXYCYCLINE; GLUCOCORTICOID; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTHRITIS; ARTICLE; CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS; CASE REPORT; CHRONIC DISEASE; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMAGE ANALYSIS; KNEE ARTHRITIS; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; CHONDROCALCINOSIS; DRUG ANTAGONISM; ECHOGRAPHY; KNEE; METHODOLOGY; MIDDLE AGED;

ANTIRHEUMATIC AGENTS; CALCIUM PYROPHOSPHATE; CHONDROCALCINOSIS; CHRONIC DISEASE; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; KNEE JOINT; MIDDLE AGED; ULTRASONOGRAPHY;

EID: 84868193590     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31826149a2     Document Type: Article

References (9)

1. Zhang W, Neame R, Doherty S, et al. Relative risk of knee chondrocalcinosis in siblings of index cases with pyrophosphate arthropathy. Ann Rheum Dis. 2004;63:969-973. (Pubitemid 38961923)
2. Musacchio E, Ramonda R, Perissinotto E, et al. The impact of knee and hip chondrocalcinosis on disability in older people: The ProVA Study from northeastern Italy. Ann Rheum Dis. 2011;70:1937-1943.
3. Doherty M, Dieppe PA. Acute pseudogout: crystal shedding or acute crystallization? Arthritis Rheum. 1981;24:954-957. (Pubitemid 11070101)
4. Martinon F, Petrilli V, Mayor A, et al. Gout-Associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-241. (Pubitemid 43372104)
5. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:R28.
6. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 2008;58:631-633. (Pubitemid 351294902)
7. Announ N, Palmer G, Guerne PA, et al. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009;76:424-426.
8. Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986;13:804-805. (Pubitemid 16015652)
9. Li W, Lam MS, Birkeland A, et al. Cell-based assays for profiling activity and safety properties of cancer drugs. J Pharmacol Toxicol Methods. 2006;54:313-319. (Pubitemid 44636258)